The purpose of this study was to investigate plasma levels of sRAGE and the RAGE ligand S100B in individuals with metabolic disturbances such as obesity, impaired fasting glucose, elevated amylin, and T2DM comorbid with AD. This evidence concerns the gene IAPP and Alzheimer disease.